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In making its recommendations the Group set out a number of objectives. 
(a) Any staging protocol should be simple and widely applicable, without being 
limited to the lowest common demoninator. 
(b) The staging protocol should be sequential and logical, avoiding unnecessary 
tests which might prove expensive and invasive. 
(c) The staging protocol proceeds to identify patients suitable for treatment with 
curative intent since there is no purpose to staging for palliative therapy. 
(d) The staging protocol should be applicable to good clinical practice with all 
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forms of therapy. There would be no restriction on institutional preference for 
additional investigations, nor additional requirements for trial purposes. 
In making its recommendations the group made the following assumptions. 
(a) Any staging protocol would be TNM based (UICC or AJC equivalent) 
(b) The staging protocol covered only non-small cell lung cancer (NSCLC) 
(c) No recommendations were made regarding which groups might be appropriate 
for different forms of therapy. This was deemed to be the domain of individual 
clinicians and their institutions. 
(d) We assumed that the diagnosis already had been established. 
(e) Patient suitability should be separately assessed, and we assumed that each pa- 
tient was lit for all forms of therapy. 
The staging protocol involves 3 steps, as outlined in the following tables. 
Step I 




















Aspiration of effusion 
(considered positive if 
cytology malignant) 
As for high risk patients 
in Step II 
If still thought suitable for curative therapy proceed to Step II. 
Step II 
Investigation Patient group Confirmatory tests 
Bronchoscopy All patients with central 
tumours or those in whom 
central extension is suspected 
The features of proximal, extrin- 
sic compression are unreliable 
and require further evaluation of 
the mediastinum by CT and/or 
mediastinal exploration 
Bone scan High risk groupa Skeletal X-rays f CT/MRI of 
bone if dubious positive result 
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CT chest and upper abdomen All patients if available Dubious findings confirmed (not 
(to lower pole of kidneys, necessarily histological) 
with i.v. contrast enhancement 
of mediastinal vessels) 
Liver ultrasound 
Brain assessment by CT or 
MRI 
High risk groupa if CT of ab- 
domen not available 
Advisable in high risk groupa 
??Unexplained anaemia (Hb < II G%) 
?? Unexplained weight loss (>8 lb (3 kg) in 6112) 
??Abnormal alk phosphatase, or transaminase 
??Where any clinical suspicion of metastatic disease 
??Patients with stage III disease 
aHigh risk patients are those having non-specific features identified by Hooper et al. (1987) Am Rev 
Respr Dis 118: 279. 
If still thought suitable for curative treatment proceed to Step III. 
Step III 
Investigation Patient group 
(a) Bronchoscopy if not previously undertaken All patients 
(b) Thoracoscopy or video assisted If pleural effusion present, thoracoscopy 
cytology negative but clinical suspicion remains 
(c) Mediastinal exploration 




Patients in whom CT suggests mediastinal inva- 
sion or if CT shows nodes> I.0 ems 
??Additional evaluation of the subaortic 
fossa by left anterior mediastinotomy 
The above groups with tumours of the left upper 
lobe and left main bronchus 
??This must be performed intra- 
operatively 
All patients - including those whose 
mediastinum has been assessed preoperatively 
?? Palpation insufficient 
??Careful and extensive mediastinal 
dissection 
??Separate labeling as per Naruke or 
ATS of excised nodes for subsequent 
histological examination (only Nl 
nodes on resection specimen) 
?? Re-evaluation of T stage 
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Proceed with definitive therapy, which will be surgical resection in all but the most 
unusual circumstances. 
Postscript 
The Group considered other tests which may be of value but made no recommen- 
dations as these tests are not universally available or acceptable and require vali- 
dation. 
